An interventional study of Urea and Placebo in Arginine Vasopressin Deficiency and Primary Polydipsia, sponsored by University Hospital, Basel, Switzerland. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-09.
Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Diabetes Insipidus, Neurogenic by University Hospital, Basel, Switzerland — 7 open to participants now, 7 under way, none of them phase 3. Diabetes Insipidus, Neurogenic · University Hospital, Basel, Switzerland.
Among the 11 studies in Diabetes Insipidus, Neurogenic by University Hospital, Basel, Switzerland, this one is the 3rd largest by enrollment, is the only one that started in 2023, is one of 8 with no phase, and was the 3rd registered.
27 studies on the registry are indexed under Diabetes Insipidus, Neurogenic; 12 are open to participants now.
Browse Diabetes Insipidus, Neurogenic studies →7 of the 11 studies in Diabetes Insipidus, Neurogenic by University Hospital, Basel, Switzerland are open now, in 3 countries. Recruiting first, the newest first:
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+ · Healthy volunteers
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18–50 · Healthy volunteers
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+ · Healthy volunteers
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 11 Diabetes Insipidus, Neurogenic studies recruiting now, 8 (73%) set no upper age limit and 3 (27%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is above the median of 42 across 23 interventional studies indexed under Diabetes Insipidus, Neurogenic.
Median enrollment 42 across the 11 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.
4 of the studies in Diabetes Insipidus, Neurogenic by University Hospital, Basel, Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06808516University Hospital, Basel, SwitzerlandEffects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls | 2026-12 |
| NCT06789705University Hospital, Basel, SwitzerlandPlasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls | 2026-12 |
| NCT07361263University Hospital, Basel, SwitzerlandPlasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency | 2027-02 |
| NCT06676774University Hospital, Basel, SwitzerlandEffect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls | 2027-02 |
Add all 4 to your calendar (.ics) → With an account.
Among the 11 studies in Diabetes Insipidus, Neurogenic by University Hospital, Basel, Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to investigate whether oral urea stimulates copeptin release and, if so, whether it may provide a novel diagnostic test in the differentiation between AVP-D (Arginine vasopressin deficiency) and PP (primary polydipsia).
This study consists of two parts, including healthy adults (study part 1 - proof of concept) and adults with an established diagnosis of PP or AVP-D (study part 2 - pilot study).
If the results of study part 1 suggest that oral urea is a potent stimulator of copeptin in healthy adults, study part 2 will be conducted, meaning that adults with an established diagnosis of PP or AVP-D will be included. If study part 1 demonstrates no relevant copeptin increase in response to oral urea, the study will be terminated thereafter and study part 2 will not be conducted.
Healthy volunteers
Inclusion Criteria:
Exclusion Criteria:
Patients
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo a diagnostic test with a single weight-adapted dose of oral urea first. After a a wash-out phase of at least 3 days and not more than 28 days participants will undergo a second diagnostic test with a single weight-adapted dose of placebo.
Diagnostic Test: Urea · Diagnostic Test: Placebo
Participants will undergo a diagnostic test with a single weight-adapted dose of placebo first. After a a wash-out phase of at least 3 days and not more than 28 days participants will undergo a second diagnostic test with a single weight-adapted dose of urea.
Diagnostic Test: Urea · Diagnostic Test: Placebo
Participants will undergo a diagnostic test with a single weight-adapted dose of oral urea
Diagnostic Test: Urea
Diagnostic test with a single weight-adapted dose of oral urea dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid). The investigators will make use of the lemon-lime flavor to soften the bitter taste of urea. - Dose calculation: 0.5 g urea/kg body weight (rounded to no decimal places), with a minimal dose of 30g and a maximal dose of 45g.
Diagnostic test with a single weight-adapted dose of placebo dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid). The placebo will contain a mixture of bitter herbal substances to mimic the taste of urea. - Dose calculation: 22 ml of placebo containing 20 ml Ergytonyl®, 1 ml Carmol®, and 1 ml Bitter Liebe®.
Difference in maximal increase in copeptin levels in plasma (pmol/l)
The difference in maximal increase in copeptin levels in plasma (pmol/l) within 150 minutes after oral intake of urea versus placebo, with the maximal increase being the difference between baseline copeptin values measured at the beginning of the test and maximal values measured between 30 and 150 minutes after ingestion.
Time frame: up to 6 time assessment until 150 minutes after baseline
Ran from Jun 2023 to primary completion in Jun 2024, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Diabetes Insipidus, Neurogenic →
University Hospital, Basel, Switzerland →